Three economists explore the viability of a UN-backed one-stop licensing ‘hub’ for making essential, often life-saving biotherapeutics and vaccines both affordable and more widely available.
Articles on Generic medicines
Displaying all articles
Prescription drug shortages can have a significant effect on quality of life for patients.
The major parties say they won’t use the PBS as a bargaining chip in US tariff negotiations. They also need to resist pressure to slow down access to generic drugs.
The Medicines Patent Pool was created to promote public health, facilitating generic licensing for patented drugs that treat diseases predominantly affecting low- and middle-income countries.
Changes in the latest federal budget will mostly affect people who need multiple medicines throughout the year, perhaps for chronic disease. But there are other ways to reduce drug costs.
Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
There are ingredients in your pills other than the one designed to treat your ailments. Those unnamed ingredients can alter how you respond to a medicine or even make you sick.
Drug shortages occur regularly in the US, even in the best of times. The pharmaceutical supply chain embodies ‘just in time’ shipping and has little built-in redundancy.
The Canadian government must undertake regular analysis of the drug shortage problem, if we are ever to develop sustainable solutions.
Academics are trained to answer important questions about health policy, and collaborating with industry on research can have a big impact.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Seven rounds of negotiations for the Regional Comprehensive Economic Partnership have already taken place with virtually no public debate. The next round of negotiations begins today in Kyoto, Japan.
Generic medicine contains the same active ingredient in the same dose as the original brand.
More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in…
Gone are the good old days when medicines had simple, easy to pronounce names such as aspirin, paracetamol and morphine. Nowadays pharmaceutical companies almost seem to revel in giving drugs names that…
Those for whom Viagra is indispensable might be a little surprised that the ubiquitous blue, diamond-shaped pill was a chance discovery by a group of research pharmaceutical chemists at Pfizer’s research…
The Anti-Counterfeiting Trade Agreement (ACTA) 2011 - Twitter hashtag #ACTA - is a controversial trade agreement designed to provide for stronger enforcement of intellectual property rights. There’s been…
Top contributors
-
Professor of Public Health, La Trobe University
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Quintiles Professor of Pharmaceutical Development and Regulatory Innovation, Schaeffer Center for Health Policy and Economics, University of Southern California
-
Practitioner Teacher, University of Technology Sydney
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Lecturer in Law, Ulster University
-
Fellow, Australian National University
-
Director of Health Policy, USC Schaeffer Center, and Associate Professor, University of Southern California
-
Dean of the Sol Price School of Public Policy; Distinguished Professor of Pharmacy, Public Policy, and Economics, University of Southern California
-
Professor in Intellectual Property and Innovation Law, Queensland University of Technology
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Postdoctoral Fellow in Quality of Medical Products, University of California, San Francisco
-
Assistant Professor, Department of Family and Community Medicine, University of Toronto
-
Professor of Health Economics, The University of Melbourne
-
Professor of Industrial and Operations Engineering, University of Michigan